GlassScriptPhysician profile
Myron H Jacobs
NPI 1255322731
$8,474.33
in general payments reported to CMS, 2019-2025
39 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,278 · 2020: $1,612 · 2021: $1,432 · 2022: $2,026 · 2023: $608 · 2024: $409 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,315.94 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,089.89 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $945.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $943.27 | 2019-2025 | Breztri, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $482.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $376.70 | 2019-2023 | |
| Grifols USA, LLC | $366.07 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $336.10 | 2019-2024 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $288.45 | 2019-2024 | Dupixent |
| Genentech USA, INC. | $269.90 | 2019-2020 | |
| Amgen INC. | $204.43 | 2022-2023 | Tezspire |
| Electromed, INC. | $182.23 | 2021-2024 | Smartvest |
| Insmed, INC. | $177.95 | 2019-2022 | |
| Mylan Specialty L.P. | $146.46 | 2019-2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $133.00 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myron Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.